CE18 - Innovation biomédicale

CK2 inhibitors as chemobiological tools to unravel CK2 role in SARS-COV-2 lifecycle and as potential antivirals with broad-anti-coronavirus activity – CK2COV

Submission summary

In 2020, the global phosphorylation landscape of SARS-CoV-2 infection was revealed, showing that phosphorylation signalling represents a primary host response to viral infection. In this study, casein kinase II (CK2) appeared to be involved in SARS-CoV-2 lifecycle, suggesting that targeting CK2 should be an interesting strategy to impair SARS-COV-2 lifecycle. We have recently developed a series of highly selective CK2 inhibitors. Here, we propose to optimise our CK2 inhibitors in order to generate chemobiological tools to further investigate CK2 role. We will identify the viral partner(s) involved in CK2-dependent regulation of SARS-CoV-2 lifecycle and reveal the CK2-dependent subcellular distribution of SARS-CoV-2 protein(s). Our objective is also to develop CK2 inhibitors exhibiting broad-spectrum antiviral activity against other human coronaviruses (HCoV-229E, OC43, NL63 and HKU1).

Project coordination

Isabelle KRIMM (Centre de Recherche en Cancérologie de Lyon)

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.

Partner

CRCL Centre de Recherche en Cancérologie de Lyon
IMRB Institut Mondor de recherche biomédicale

Help of the ANR 423,999 euros
Beginning and duration of the scientific project: December 2021 - 36 Months

Useful links

Explorez notre base de projets financés

 

 

ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter